Cargando…
Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus
OBJECTIVES: High rates of anti-drug antibodies (ADA) to rituximab have been demonstrated in patients undergoing treatment for SLE. However, little is known with regard to their long-term dynamics, impact on drug kinetics and subsequent implications for treatment response. In this study, we aimed to...
Autores principales: | Wincup, Chris, Dunn, Nicky, Ruetsch-Chelli, Caroline, Manouchehrinia, Ali, Kharlamova, Nastya, Naja, Meena, Seitz-Polski, Barbara, Isenberg, David A, Fogdell-Hahn, Anna, Ciurtin, Coziana, Jury, Elizabeth C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321108/ https://www.ncbi.nlm.nih.gov/pubmed/36370065 http://dx.doi.org/10.1093/rheumatology/keac608 |
Ejemplares similares
-
The role of herpesvirus 6A and 6B in multiple sclerosis and epilepsy
por: Dunn, Nicky, et al.
Publicado: (2020) -
First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis
por: Faustini, Francesca, et al.
Publicado: (2021) -
Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier
por: Kharlamova, Nastya, et al.
Publicado: (2020) -
Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach
por: Robinson, George A, et al.
Publicado: (2020) -
Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE
por: Robinson, George A., et al.
Publicado: (2021)